Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries.
Caroline Catt, Johanna M Pfeil, Daniel Barthelmes...
https://pubmed.ncbi.nlm.nih.gov/37704267/Actively Recruiting
Led by University Medicine Greifswald · Updated on 2024-01-24
3000
Participants Needed
59
Research Sites
52 weeks
Total Duration
This research aims to collect comprehensive information on infants treated for retinopathy of prematurity ROP across multiple European countries. It is an observational registry study designed to gather data on the natural history of severe ROP, including variations in the diseases clinical features and progression, as well as treatment and follow-up patterns. The study is open-ended and includes infants regardless of the treatment method used at participating centers. The study involves enrolling preterm infants who require treatment for ROP according to national guidelines. No additional examinations or interventions are performed beyond routine clinical care. Data collected include baseline characteristics, treatment details at initial therapy and any re-treatments, and the stage of ROP through follow-up. Long-term ophthalmic and neurological development will also be tracked for up to 18 years. Participants clinical routine data are collected and documented electronically, focusing on treatment timing, disease progression, and outcomes. The primary outcomes include baseline data from birth to treatment, treatment parameters, and ROP stage through follow-up, typically spanning from birth to about one year. Secondary outcomes assess long-term eye and neurological health. This registry does not involve active treatment assignment and continues collecting data from infants treated at participating centers.
CONDITIONS
European Disease Registry on Retinopathy of Prematurity (ROP)
A
Andreas Stahl, Professor
J
Johanna M Pfeil, Dr
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Medicine Greifswald
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From birth to approximately 18 years postnatal age
Participants who undergo routine care for treatment-requiring retinopathy of prematurity are observed and their treatment parameters and disease progression are documented.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Caroline Catt, Johanna M Pfeil, Daniel Barthelmes...
https://pubmed.ncbi.nlm.nih.gov/37704267/K Winter, J M Pfeil, H Engmann...
https://pubmed.ncbi.nlm.nih.gov/37725047/University Medicine Greifswald
Lead Sponsor